Browsing by Subject "Biorepository"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    The National Gene Vector Biorepository's Pharm/Tox Database
    (Elsevier, 2009-04-01) Cornetta, Kenneth; Matheson, Lorraine; Medical and Molecular Genetics, School of Medicine
  • Thumbnail Image
    Item
    NCRAD: Academic Biorepository to Support Standardization and Efficacy of Clinical Research Biospecimens for the Advancement of AD/ADRD Research
    (Wiley, 2025-01-03) Snoddy, Casey; Faber, Kelley M.; Lacy, Kaci; Jackson, Jacqueline M.; Foroud, Tatiana M.; Medical and Molecular Genetics, School of Medicine
    Background: NCRAD is a National Institute on Aging (NIA) cooperative grant, awarded to Indiana University since 1990, whose purpose is to serve as a biorepository for AD/ADRD researchers. With 74 participating across 150 unique institutions, NCRAD links specimens to clinical research data. NCRAD maintains over 2 million aliquots from more than 126,000 research participants spanning a wide range of AD/ADRD related phenotypes as well as healthy controls. Method: To ensure standardization and uniformity, NCRAD develops a manual of procedures specific to each study protocol that includes detailed pictures, schematics, and flow charts for each sample type collected. NCRAD conducts web‐based training for site staff and provides supplemental training videos to ensure Researchers receiving samples from NCRAD agree to share the data generated from the samples. Since its inception, NCRAD has distributed over 410,000 samples to more than 200 researchers. NCRAD biospecimens and data have been reported in more than 850 publications. Result: NCRAD’s mission is to maintain uniformity in collection and processing of samples sites involved in each study. Centralized biobanking and broad sharing of biospecimens has accelerated research discovery. Conclusion: Using standardized biospecimen collection, processing, shipping, storage, and distribution procedures established at NCRAD, in conjunction with attention to detail, strict compliance with regulations, and oversight from the NIA, has resulted in a biorepository with highest quality samples available to researchers investigating the etiology, early detection and therapeutic development for AD/ADRD.
  • Thumbnail Image
    Item
    PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies: Rationale and Study Design for PROCEED From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer
    (Wolters Kluwer, 2018-11) Yadav, Dhiraj; Park, Walter G.; Fogel, Evan L.; Li, Liang; Chari, Suresh T.; Feng, Ziding; Fisher, William E.; Forsmark, Christopher E.; Jeon, Christie Y.; Habtezion, Aida; Hart, Phil A.; Hughes, Steven J.; Othman, Mohamed O.; Rinaudo, Jo Ann; Pandol, Stephen J.; Tirkes, Temel; Serrano, Jose; Srivastava, Sudhir; Van Den Eeden, Stephen K.; Whitcomb, David C.; Topazian, Mark; Conwell, Darwin L.; Medicine, School of Medicine
    Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.
  • Thumbnail Image
    Item
    Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Type 1 Diabetes in Acute Pancreatitis Consortium
    (Wolters Kluwer, 2022) Wasserfall, Clive; Dyer, Anne-Marie; Speake, Cate; Andersen, Dana K.; Baab, Kendall Thomas; Bellin, Melena D.; Broach, James R.; Campbell-Thompson, Martha; Chinchilli, Vernon M.; Lee, Peter J.; Park, Walter G.; Pratley, Richard E.; Saloman, Jami L.; Sims, Emily K.; Tang, Gong; Yadav, Dhiraj; Yazici, Cemal; Conwell, Darwin L.; Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC); Pediatrics, School of Medicine
    Differences in methods for biospecimen collection, processing, and storage can yield considerable variability and error. Therefore, best practices for standard operating procedures are critical for successful discovery, development, and validation of disease biomarkers. Here, we describe standard operating procedures developed for biospecimen collection during the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) Study within the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC). Notably these protocols were developed using an integrative process based on prior consortium experience and with input from working groups with expertise in immunology, pancreatitis and diabetes. Publication and adoption consistent biospecimen protocols will inform future studies and allow for better comparisons across different metabolic research efforts.